Bone Biologics Co. (NASDAQ:BBLG) Short Interest Update

Bone Biologics Co. (NASDAQ:BBLG) saw a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 193,300 shares, a growth of 48.2% from the February 13th total of 130,400 shares. Based on an average daily trading volume, of 218,900 shares, the days-to-cover ratio is presently 0.9 days. Currently, 36.2% of the shares of the stock are short sold.

Bone Biologics Stock Performance

NASDAQ:BBLG opened at $0.83 on Friday. Bone Biologics has a 1-year low of $0.71 and a 1-year high of $4.25. The business has a 50 day moving average of $0.99 and a 200 day moving average of $1.27.

About Bone Biologics

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.